Full text is available at the source.
A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma
Testing timed temozolomide treatment based on body clock in brain tumor patients
AI simplified
Abstract
A total of 35 evaluable patients with gliomas were analyzed for the feasibility of timed delivery of temozolomide (TMZ).
- Patients were randomized to receive TMZ either in the morning before 10 am or in the evening after 8 pm.
- Compliance with the timed dosing of TMZ was demonstrated.
- There were no significant differences in adverse events between morning and evening dosing.
- Quality of life measures showed no significant differences between the two treatment groups.
- Overall survival rates did not differ significantly between the morning and evening administration.
AI simplified